Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1587475
PUBLISHER: Grand View Research | PRODUCT CODE: 1587475
U.S. Clinical Trials Market Size, Share & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Indication, By Study Design, By Indication by Study Design, By Sponsor, By Service, And Segment Forecasts, 2025 - 2030
PUBLISHED:
PAGES: 100 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
U.S. Clinical Trials Market Growth & Trends:
The U.S. clinical trials market size is estimated to reach USD 57.79 billion by 2030, registering a CAGR of 6.30% from 2025 to 2030, according to a new report by Grand View Research, Inc. The increasing prevalence of chronic disease and growing demand for clinical trials in the U.S. is boosting the growth of the market.
The number of people diagnosed with cancer is expected to increase multi-fold in the coming eight years. Although survivors have increased considerably owing to research in the oncology field, the number of cancer patients is expected to increase across the world. Pancreatic cancer has a poor prognosis with a survival of only 1 to 3 years. Approximately 13 people are diagnosed with GI stromal tumors each day. More than 60, 000 new cases of renal cell carcinoma are diagnosed every year in the U.S. Hence, representing an increasing prevalence of cancer and the need for effective treatments against various types of cancer. Investment in R&D is expected to grow owing to the disease prevalence across the U.S. thereby boosting the industry's growth.
The COVID-19 pandemic has halted new research projects and reallocated resources for other diseases. The supply chain for clinical trial samples has also been interrupted as a result of blocked borders. Hence, this market is disrupted. However, the COVID-19 response has resulted in new developments on the market that have transformed the conduct of clinical trials. Decentralized/virtual clinical trials are one such technique. Virtual trials have a very important role in the current COVID-19 scenario. As a result of the virtual visit and remote patient monitoring, participants have a choice and peace of mind to minimize risks. Monitoring gadgets, software tools, and mobile phones enable participants to complete the experiment from their homes.
U.S. Clinical Trials Market Report Highlights:
- In 2024, the phase III dominated the market with highest revenue share. These trials are more crucial as they involve 300 to 3000 participants and have a longer period of time. Thus, it is the most expensive phase
- By study design, the interventional design segment dominated the U.S. market and accounted for the largest revenue share in 2024.
- Based on indication, the oncology segment held the largest revenue share in 2024. This growth is due to the growing number of cases of cancer. Thus, a large amount of expenditure is spent on oncology clinical trials.
Product Code: GVR-4-68039-580-4
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Estimates and forecast timeline
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.6.1. Commodity flow analysis (Model 1)
- 1.6.1.1. Approach 1: Commodity flow approach
- 1.6.2. Volume price analysis (Model 2)
- 1.6.2.1. Approach 2: Volume price analysis
- 1.6.1. Commodity flow analysis (Model 1)
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
- 1.9.1. Objective 1
- 1.9.2. Objective 2
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.3. Competitive Insights
Chapter 3. U.S. Clinical Trials Market Variables, Trends, & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent Market Outlook
- 3.1.2. Ancillary Market Outlook
- 3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
- 3.3. Regulatory Landscape
- 3.4. Technological Landscape
- 3.5. Pricing Model Analysis
- 3.6. Clinical Trial Volume Analysis, 2024
- 3.7. U.S. Clinical Trials Market Analysis Tools
- 3.7.1. Porter's Five Forces Analysis
- 3.7.2. PESTEL Analysis
- 3.7.3. COVID-19 Impact Analysis
- 3.8. Product Pipeline Analysis by Stage
- 3.8.1. Therapeutics in Development
- 3.8.2. Vaccines in Development
Chapter 4. U.S. Clinical Trials Market: Phase Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Clinical Trials Market: Phase Movement Analysis & Market Share, 2024 & 2030
- 4.3. Phase I
- 4.3.1. Phase I Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.4. Phase II
- 4.4.1. Phase II Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.5. Phase III
- 4.5.1. Phase III Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 4.6. Phase IV
- 4.6.1. Phase IV Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 5. U.S. Clinical Trials Market: Study Design Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Clinical Trials Market: Study Design Movement Analysis & Market Share, 2024 & 2030
- 5.3. Interventional
- 5.3.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.4. Observational
- 5.4.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 5.5. Expanded Access
- 5.5.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 6. U.S. Clinical Trials Market: Indication Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Clinical Trials Market: Indication Movement Analysis & Market Share, 2024 & 2030
- 6.3. Autoimmune/Inflammation
- 6.3.1. Autoimmune/Inflammation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.2. Rheumatoid Arthritis
- 6.3.2.1. Rheumatoid Arthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.3. Multiple Sclerosis
- 6.3.3.1. Multiple Sclerosis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.4. Osteoarthritis
- 6.3.4.1. Osteoarthritis Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.5. Irritable Bowel Syndrome (IBS)
- 6.3.5.1. Irritable Bowel Syndrome (IBS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.3.6. Others
- 6.3.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4. Pain Management
- 6.4.1. Pain Management Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.2. Chronic Pain
- 6.4.2.1. Chronic Pain Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.4.3. Acute Pain
- 6.4.3.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5. Oncology
- 6.5.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.2. Blood Cancer
- 6.5.2.1. Blood Cancer Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.3. Solid Tumors
- 6.5.3.1. Solid Tumors Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.5.4. Others
- 6.5.4.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6. CNS Conditions
- 6.6.1. CNS Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.2. Epilepsy
- 6.6.2.1. Epilepsy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.3. Parkinson's Disease (PD)
- 6.6.3.1. Parkinson's Disease (PD) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.4. Huntington's Disease
- 6.6.4.1. Huntington's Disease Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.5. Stroke
- 6.6.5.1. Stroke Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.6. Traumatic Brain Injury (TBI)
- 6.6.6.1. Traumatic Brain Injury (TBI) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.7. Amyotrophic Lateral Sclerosis (ALS)
- 6.6.7.1. Amyotrophic Lateral Sclerosis (ALS) Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.8. Muscle Regeneration
- 6.6.8.1. Muscle Regeneration Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.6.9. Others
- 6.6.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.7. Diabetes
- 6.7.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.8. Obesity
- 6.8.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.9. Cardiovascular
- 6.9.1. Cardiovascular Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 6.10. Others
- 6.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 7. U.S. Clinical Trials Market: Indication by Study Design Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Clinical Trials Market: Indication Movement Analysis & Market Share, 2024 & 2030
- 7.3. Autoimmune/Inflammation
- 7.3.1. Autoimmune/Inflammation Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.2. Interventional
- 7.3.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.3. Observational
- 7.3.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.3.4. Expanded Access
- 7.3.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4. Pain Management
- 7.4.1. Pain Management Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.2. Interventional
- 7.4.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.3. Observational
- 7.4.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.4.4. Expanded Access
- 7.4.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5. Oncology
- 7.5.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.2. Interventional
- 7.5.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.3. Observational
- 7.5.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.5.4. Expanded Access
- 7.5.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6. CNS Conditions
- 7.6.1. CNS Conditions Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.2. Interventional
- 7.6.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.3. Observational
- 7.6.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.6.4. Expanded Access
- 7.6.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7. Diabetes
- 7.7.1. Diabetes Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.2. Interventional
- 7.7.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.3. Observational
- 7.7.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.7.4. Expanded Access
- 7.7.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8. Obesity
- 7.8.1. Obesity Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.2. Interventional
- 7.8.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.3. Observational
- 7.8.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.8.4. Expanded Access
- 7.8.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.9. Cardiovascular
- 7.9.1. Cardiovascular Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.9.2. Interventional
- 7.9.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.9.3. Observational
- 7.9.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.9.4. Expanded Access
- 7.9.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.10. Others
- 7.10.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.10.2. Interventional
- 7.10.2.1. Interventional Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.10.3. Observational
- 7.10.3.1. Observational Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 7.10.4. Expanded Access
- 7.10.4.1. Expanded Access Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 8. U.S. Clinical Trials Market: Service Estimates & Trend Analysis
- 8.1. Segment Dashboard
- 8.2. Clinical Trials Market: Sponsor Movement Analysis & Market Share, 2024 & 2030
- 8.3. Protocol Designing
- 8.3.1. Protocol Designing Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.4. Site Identification
- 8.4.1. Site Identification Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.5. Patient Recruitment
- 8.5.1. Patient Recruitment Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.6. Laboratory Services
- 8.6.1. Laboratory Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.7. Bioanalytical Testing Services
- 8.7.1. Bioanalytical Testing Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.8. Clinical Trial Data Management Services
- 8.8.1. Clinical Trial Data Management Services Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 8.9. Others
- 8.9.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 9. U.S. Clinical Trials Market: Sponsor Estimates & Trend Analysis
- 9.1. Segment Dashboard
- 9.2. Clinical Trials Market: Sponsor Movement Analysis & Market Share, 2024 & 2030
- 9.3. Pharmaceutical & Biopharmaceutical Companies
- 9.3.1. Pharmaceutical & Biopharmaceutical Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
- 9.4. Medical Device Companies
- 9.4.1. Medical Device Companies Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
Chapter 10. Competitive Landscape
- 10.1. Market Participant Categorization
- 10.1.1. Market Leaders
- 10.1.2. Emerging Players
- 10.2. Market Position Analysis, 2024
- 10.3. Key Company Profiles
- 10.3.1. IQVIA
- 10.3.1.1. Company Overview
- 10.3.1.2. Financial Performance
- 10.3.1.3. Service Benchmarking
- 10.3.1.4. Strategic Initiatives
- 10.3.2. Fortrea Inc.
- 10.3.2.1. Company Overview
- 10.3.2.2. Financial Performance
- 10.3.2.3. Service Benchmarking
- 10.3.2.4. Strategic Initiatives
- 10.3.3. PAREXEL International Corporation
- 10.3.3.1. Company Overview
- 10.3.3.2. Financial Performance
- 10.3.3.3. Service Benchmarking
- 10.3.3.4. Strategic Initiatives
- 10.3.4. Thermo Fisher Scientific Inc.
- 10.3.4.1. Company Overview
- 10.3.4.2. Financial Performance
- 10.3.4.3. Service Benchmarking
- 10.3.4.4. Strategic Initiatives
- 10.3.5. Charles River Laboratories
- 10.3.5.1. Company Overview
- 10.3.5.2. Financial Performance
- 10.3.5.3. Service Benchmarking
- 10.3.5.4. Strategic Initiatives
- 10.3.6. ICON Plc
- 10.3.6.1. Company Overview
- 10.3.6.2. Financial Performance
- 10.3.6.3. Service Benchmarking
- 10.3.6.4. Strategic Initiatives
- 10.3.7. Wuxi AppTec Inc.
- 10.3.7.1. Company Overview
- 10.3.7.2. Financial Performance
- 10.3.7.3. Service Benchmarking
- 10.3.7.4. Strategic Initiatives
- 10.3.8. Medpace
- 10.3.8.1. Company Overview
- 10.3.8.2. Financial Performance
- 10.3.8.3. Service Benchmarking
- 10.3.8.4. Strategic Initiatives
- 10.3.9. Syneos Health
- 10.3.9.1. Company Overview
- 10.3.9.2. Financial Performance
- 10.3.9.3. Service Benchmarking
- 10.3.9.4. Strategic Initiatives
- 10.3.10. AstraZeneca
- 10.3.10.1. Company Overview
- 10.3.10.2. Financial Performance
- 10.3.10.3. Service Benchmarking
- 10.3.10.4. Strategic Initiatives
- 10.3.11. Merck & Co.
- 10.3.11.1. Company Overview
- 10.3.11.2. Financial Performance
- 10.3.11.3. Service Benchmarking
- 10.3.11.4. Strategic Initiatives
- 10.3.12. Eli Lilly and Company
- 10.3.12.1. Company Overview
- 10.3.12.2. Financial Performance
- 10.3.12.3. Service Benchmarking
- 10.3.12.4. Strategic Initiatives
- 10.3.13. Novo Nordisk A/S
- 10.3.13.1. Company Overview
- 10.3.13.2. Financial Performance
- 10.3.13.3. Service Benchmarking
- 10.3.13.4. Strategic Initiatives
- 10.3.14. Pfizer
- 10.3.14.1. Company Overview
- 10.3.14.2. Financial Performance
- 10.3.14.3. Service Benchmarking
- 10.3.14.4. Strategic Initiatives
- 10.3.15. Caidya
- 10.3.15.1. Company Overview
- 10.3.15.2. Financial Performance
- 10.3.15.3. Service Benchmarking
- 10.3.15.4. Strategic Initiatives
- 10.3.1. IQVIA
Product Code: GVR-4-68039-580-4
List of Tables
- Table 1. List of Secondary Sources
- Table 2. List of Abbreviations
- Table 3. U.S. Clinical Trials Market, by Phase, 2018 - 2030 (USD Million)
- Table 4. U.S. Clinical Trials Market, by Study Design, 2018 - 2030 (USD Million)
- Table 5. U.S. Clinical Trials Market, by Indication, 2018 - 2030 (USD Million)
- Table 6. U.S. Clinical Trials Market, Indication by Study Design, 2018 - 2030 (USD Million)
- Table 7. U.S. Clinical Trials Market, by Service, 2018 - 2030 (USD Million)
- Table 8. U.S. Clinical Trials Market, by Sponsor, 2018 - 2030 (USD Million)
- Table 9. Participant's Overview
- Table 10. Financial Performance
- Table 11. Service Benchmarking
- Table 12. Strategic Initiatives
List of Figures
- Fig. 1 Information Procurement
- Fig. 2 Primary Research Pattern
- Fig. 3 Market Research Approaches
- Fig. 4 Value Chain-Based Sizing & Forecasting
- Fig. 5 Market Formulation & Validation
- Fig. 6 Clinical Trials Market, Market Segmentation
- Fig. 7 Market Driver Relevance Analysis (Current & Future Impact)
- Fig. 8 Market Restraint Relevance Analysis (Current & Future Impact)
- Fig. 9 Market Challenge Relevance Analysis (Current & Future Impact)
- Fig. 10 PESTEL by SWOT Analysis
- Fig. 11 Porter's Five Forces Analysis
- Fig. 12 U.S. Clinical Trials Market, for Phase I, 2018 - 2030 (USD Million)
- Fig. 13 U.S. Clinical Trials Market, for Phase II, 2018 - 2030 (USD Million)
- Fig. 14 U.S. Clinical Trials Market, for Phase III, 2018 - 2030 (USD Million)
- Fig. 15 U.S. Clinical Trials Market, for Phase IV, 2018 - 2030 (USD Million)
- Fig. 16 U.S. Clinical Trials Market, for Interventional, 2018 - 2030 (USD Million)
- Fig. 17 U.S. Clinical Trials Market, for Observational, 2018 - 2030 (USD Million)
- Fig. 18 U.S. Clinical Trials Market, for Expanded Access, 2018 - 2030 (USD Million)
- Fig. 19 U.S. Clinical Trials Market, for Autoimmune/Inflammation, 2018 - 2030 (USD Million)
- Fig. 20 U.S. Clinical Trials Market, for Rheumatoid Arthritis, 2018 - 2030 (USD Million)
- Fig. 21 U.S. Clinical Trials Market, for Multiple Sclerosis, 2018 - 2030 (USD Million)
- Fig. 22 U.S. Clinical Trials Market, for Osteoarthritis, 2018 - 2030 (USD Million)
- Fig. 23 U.S. Clinical Trials Market, for Irritable Bowel Syndrome (IBS), 2018 - 2030 (USD Million)
- Fig. 24 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)
- Fig. 25 U.S. Clinical Trials Market, for Pain Management, 2018 - 2030 (USD Million)
- Fig. 26 U.S. Clinical Trials Market, for Chronic Pain, 2018 - 2030 (USD Million)
- Fig. 27 U.S. Clinical Trials Market, for Acute Pain, 2018 - 2030 (USD Million)
- Fig. 28 U.S. Clinical Trials Market, for Oncology, 2018 - 2030 (USD Million)
- Fig. 29 U.S. Clinical Trials Market, for Blood Cancer, 2018 - 2030 (USD Million)
- Fig. 30 U.S. Clinical Trials Market, for Solid Tumors, 2018 - 2030 (USD Million)
- Fig. 31 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)
- Fig. 32 U.S. Clinical Trials Market, for CNS Conditions, 2018 - 2030 (USD Million)
- Fig. 33 U.S. Clinical Trials Market, for Epilepsy, 2018 - 2030 (USD Million)
- Fig. 34 U.S. Clinical Trials Market, for Parkinson's Disease (PD), 2018 - 2030 (USD Million)
- Fig. 35 U.S. Clinical Trials Market, for Huntington's Disease, 2018 - 2030 (USD Million)
- Fig. 36 U.S. Clinical Trials Market, for Stroke, 2018 - 2030 (USD Million)
- Fig. 37 U.S. Clinical Trials Market, for Traumatic Brain Injury (TBI), 2018 - 2030 (USD Million)
- Fig. 38 U.S. Clinical Trials Market, for Amyotrophic Lateral Sclerosis (ALS), 2018 - 2030 (USD Million)
- Fig. 39 U.S. Clinical Trials Market, for Muscle Regeneration, 2018 - 2030 (USD Million)
- Fig. 40 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)
- Fig. 41 U.S. Clinical Trials Market, for Diabetes, 2018 - 2030 (USD Million)
- Fig. 42 U.S. Clinical Trials Market, for Obesity, 2018 - 2030 (USD Million)
- Fig. 43 U.S. Clinical Trials Market, for Cardiovascular, 2018 - 2030 (USD Million)
- Fig. 44 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)
- Fig. 45 U.S. Clinical Trials Market, for Autoimmune/Inflammation Interventional, 2018 - 2030 (USD Million)
- Fig. 46 U.S. Clinical Trials Market, for Autoimmune/Inflammation Observational, 2018 - 2030 (USD Million)
- Fig. 47 U.S. Clinical Trials Market, for Autoimmune/Inflammation Expanded Access, 2018 - 2030 (USD Million)
- Fig. 48 U.S. Clinical Trials Market, for Pain Management Interventional, 2018 - 2030 (USD Million)
- Fig. 49 U.S. Clinical Trials Market, for Pain Management Observational, 2018 - 2030 (USD Million)
- Fig. 50 U.S. Clinical Trials Market, for Pain Management Expanded Access, 2018 - 2030 (USD Million)
- Fig. 51 U.S. Clinical Trials Market, for Oncology Interventional, 2018 - 2030 (USD Million)
- Fig. 52 U.S. Clinical Trials Market, for Oncology Observational, 2018 - 2030 (USD Million)
- Fig. 53 U.S. Clinical Trials Market, for Oncology Expanded Access, 2018 - 2030 (USD Million)
- Fig. 54 U.S. Clinical Trials Market, for CNS Conditions Interventional, 2018 - 2030 (USD Million)
- Fig. 55 U.S. Clinical Trials Market, for CNS Conditions Observational, 2018 - 2030 (USD Million)
- Fig. 56 U.S. Clinical Trials Market, for CNS Conditions Expanded Access, 2018 - 2030 (USD Million)
- Fig. 57 U.S. Clinical Trials Market, for Diabetes Interventional, 2018 - 2030 (USD Million)
- Fig. 58 U.S. Clinical Trials Market, for Diabetes Observational, 2018 - 2030 (USD Million)
- Fig. 59 U.S. Clinical Trials Market, for Diabetes Expanded Access, 2018 - 2030 (USD Million)
- Fig. 60 U.S. Clinical Trials Market, for Obesity Interventional, 2018 - 2030 (USD Million)
- Fig. 61 U.S. Clinical Trials Market, for Obesity Observational, 2018 - 2030 (USD Million)
- Fig. 62 U.S. Clinical Trials Market, for Obesity Expanded Access, 2018 - 2030 (USD Million)
- Fig. 63 U.S. Clinical Trials Market, for Cardiovascular Interventional, 2018 - 2030 (USD Million)
- Fig. 64 U.S. Clinical Trials Market, for Cardiovascular Observational, 2018 - 2030 (USD Million)
- Fig. 65 U.S. Clinical Trials Market, for Cardiovascular Expanded Access, 2018 - 2030 (USD Million)
- Fig. 66 U.S. Clinical Trials Market, for Other Indications Interventional, 2018 - 2030 (USD Million)
- Fig. 67 U.S. Clinical Trials Market, for Other Indications Observational, 2018 - 2030 (USD Million)
- Fig. 68 U.S. Clinical Trials Market, for Other Indications Expanded Access, 2018 - 2030 (USD Million)
- Fig. 69 U.S. Clinical Trials Market, for Protocol Designing, 2018 - 2030 (USD Million)
- Fig. 70 U.S. Clinical Trials Market, for Site Identification, 2018 - 2030 (USD Million)
- Fig. 71 U.S. Clinical Trials Market, for Patient Recruitment, 2018 - 2030 (USD Million)
- Fig. 72 U.S. Clinical Trials Market, for Laboratory Services, 2018 - 2030 (USD Million)
- Fig. 73 U.S. Clinical Trials Market, for Bioanalytical Testing Services, 2018 - 2030 (USD Million)
- Fig. 74 U.S. Clinical Trials Market, for Clinical Trial Data Management Services, 2018 - 2030 (USD Million)
- Fig. 75 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)
- Fig. 76 U.S. Clinical Trials Market, for Pharmaceutical & Biopharmaceutical Companies, 2018 - 2030 (USD Million)
- Fig. 77 U.S. Clinical Trials Market, for Medical Device Companies, 2018 - 2030 (USD Million)
- Fig. 78 U.S. Clinical Trials Market, for Others, 2018 - 2030 (USD Million)
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.